Core Insights - The pharmaceutical sector has shown unexpected strong performance in 2023, with the China Securities Pharmaceutical Index rising over 13% and the Oriental Fortune Innovation Drug Index increasing by more than 59% year-to-date [1] - The China Europe Fund's healthcare fund has also performed well, with a one-year increase of 34.71% and a year-to-date increase of 25.45%, significantly outperforming both its peers and the CSI 300 Index [1] - Despite the recent recovery in core products, the overall situation for China Europe Fund's equity products remains concerning, with significant reductions in fund sizes compared to their peaks in 2021 [2][5] Fund Performance - As of July 7, 2023, the mixed fund size of China Europe Fund was 1,647.99 billion yuan, down from a peak of 3,368.29 billion yuan in 2021, a decrease of over 1,700 billion yuan [2][5] - The stock fund size also declined from a peak of 477.96 billion yuan in 2021 to 256.34 billion yuan in Q2 2023, a reduction of over 200 billion yuan [2][5] - Overall, the combined reduction in mixed and stock funds exceeds 1,900 billion yuan in recent years [2] Company Background - China Europe Fund was established in July 2006 and initially struggled due to management's unfamiliarity with the A-share market, missing opportunities during the 2006-2007 bull market [3] - A significant turnaround occurred in 2008 with the appointment of Liu Jianping as general manager, leading to rapid growth and the establishment of a unique employee stock ownership structure [4] Shift in Business Focus - Despite the decline in equity business, the overall scale of China Europe Fund has increased to 6,160 billion yuan as of July 22, 2023, up from 5,711.06 billion yuan during the peak of its equity business in 2021 [6] - The growth is primarily driven by fixed-income and money market funds, with bond fund sizes increasing from 696 billion yuan in Q3 2020 to 1,463 billion yuan in Q2 2023, effectively doubling [6] - The company has shifted its focus from equity to fixed-income products, attracting talent from the fixed-income sector to strengthen its offerings [6][7] Performance of Fixed-Income Products - Several fixed-income products from China Europe Fund have performed well, with notable rankings in their respective categories [7] - The company ranked TOP1 among 14 mid-sized fixed-income companies in the past year, indicating strong performance in this segment [7] Challenges Ahead - The shift towards fixed-income products may negatively impact profitability, as management fees for mixed funds are generally higher than those for bond funds [8] - The focus on fixed-income may lead to the potential loss of key fund managers, as evidenced by the departure of notable figures like Cao Mingchang [8]

Group 1 - The article emphasizes the importance of having an emergency fund before pursuing high-yield investments, suggesting that this fund should cover 6 months to 1 year of expenses [2] - It recommends using flexible cash management products for the emergency fund, such as Alipay's Yu'ebao or WeChat's Wallet, which provide stable but low returns [2] Group 2 - Once an emergency fund is established, excess funds can be allocated to fixed-income products like bank wealth management products and bond funds for higher returns [3] - Bank wealth management products are considered stable but may have a lock-in period, while bond funds offer higher returns with greater net asset value fluctuations [3] Group 3 - For funds that exceed 5 years of expenses, the article suggests investing in risk assets like ETF funds, which typically outperform actively managed funds over the long term [4] - The risk associated with ETF funds is highlighted, as they are subject to market price fluctuations and require careful consideration of the investor's risk tolerance [4] Group 4 - A specific investment strategy is proposed based on the investor's annual expenses, recommending cash management products for initial savings, followed by a mix of cash management and fixed-income products as savings grow [5] - The strategy outlines that for an investor with annual expenses of 50,000 yuan, all savings should initially go into cash management products, transitioning to fixed-income products as savings increase [5][6]

Core Viewpoint - The bond market has experienced significant fluctuations, with a focus on the strong sales performance of fixed-income products, particularly the "Hengying Stable Profit Fixed Income Daily Open 1st Phase A" product, which has accumulated sales of 599 billion yuan over the past three months [1][5]. Group 1: Product Performance - The "Hengying Stable Profit Fixed Income Daily Open 1st Phase A" product has shown a notable increase in net value in mid-March, but the growth rate has slowed since April [4]. - Despite its strong sales, the product's performance in terms of returns is average compared to similar products, particularly over the last three months and one month [4][5]. Group 2: Product Features - The product's appeal lies in its flexible holding period, allowing investors to choose their investment duration from 1 day up to 365 days, which can be adjusted after purchase [5]. - The product maintains a 0 drawdown, attributed to its low volatility strategy, primarily investing in deposits and bonds from high-quality financial institutions [5]. Group 3: Evaluation Metrics - The product received a score of 7 for returns, 100 for risk control, 27 for risk-adjusted returns, and 71 for comprehensive fees, ranking 373rd, 1st, 424th, and 41st respectively among 499 similar products, achieving an overall score that surpasses 42.28% of its peers [5]. - The evaluation process considers four dimensions: return performance (40% weight), risk control (30% weight), risk-adjusted return (20% weight), and comprehensive fees (10% weight), with the aim of identifying relatively strong products in the market [6].